Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis

Journal of Autoimmunity

Volumn 36, Issue 2, 2011, Pages 135-141

  Aricha, Revital ^a   Mizrachi, Keren ^a,b   Fuchs, Sara ^a   Souroujon, Miriam C ^a,c  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

^c OPEN UNIVERSITY OF ISRAEL   (Israel)

Author keywords

Experimental autoimmune myasthenia gravis (EAMG); IL 6; Regulatory T cells; Th17

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 21; INTERLEUKIN 23 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CELL COMPARTMENTALIZATION; CONTROLLED STUDY; DISEASE SEVERITY; DOWN REGULATION; DRUG INHIBITION; EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS; FEMALE; LYMPH NODE; MYASTHENIA GRAVIS; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY T LYMPHOCYTE; TH17 CELL; UPREGULATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; INTERLEUKIN-17; INTERLEUKIN-6; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; RATS; RATS, INBRED LEW; RECEPTORS, CHOLINERGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES, REGULATORY; TH17 CELLS;

EID: 79951943070     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2010.12.001     Document Type: Article

References (38)

1. Weaver C.T., Murphy K.M. The central role of the Th17 lineage in regulating the inflammatory/autoimmune axis. Semin Immunol 2007, 19:351-352.
2. Korn T., Oukka M., Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol 2007.
3. Ishihara K., Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002, 13:357-368.
4. Im S.H., Barchan D., Maiti P.K., Fuchs S., Souroujon M.C. Blockade of CD40 ligand suppresses chronic experimental myasthenia gravis by down-regulation of Th1 differentiation and up-regulation of CTLA-4. J Immunol 2001, 166:6893-6898.
5. Karachunski P.I., Ostlie N.S., Monfardini C., Conti-Fine B.M. Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. J Immunol 2000, 164:5236-5244.
6. Ostlie N.S., Karachunski P.I., Wang W., Monfardini C., Kronenberg M., Conti-Fine B.M. Transgenic expression of IL-10 in T cells facilitates development of experimental myasthenia gravis. J Immunol 2001, 166:4853-4862.
7. Cohen-Kaminsky S., Delattre R.M., Devergne O., Klingel-Schmitt I., Emilie D., Galanaud P., et al. High IL-6 gene expression and production by cultured human thymic epithelial cells from patients with myasthenia gravis. Ann N Y Acad Sci 1993, 681:97-99.
8. Endo S., Hasegawa T., Sato Y., Otani S., Saito N., Tetsuka K., et al. Inhibition of IL-6 overproduction by steroid treatment before transsternal thymectomy for myasthenia gravis: does it help stabilize perioperative condition?. Eur J Neurol 2005, 12:768-773.
9. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990, 8:253-278.
10. Chen-Kiang S. Regulation of terminal differentiation of human B-cells by IL-6. Curr Top Microbiol Immunol 1995, 194:189-198.
11. Takatsu K. Cytokines involved in B-cell differentiation and their sites of action. Proc Soc Exp Biol Med 1997, 215:121-133.
12. Deng C., Goluszko E., Tuzun E., Yang H., Christadoss P. Resistance to experimental autoimmune myasthenia gravis in IL-6-deficient mice is associated with reduced germinal center formation and C3 production. J Immunol 2002, 169:1077-1083.
13. Bai Y., Liu R., Huang D., La Cava A., Tang Y.Y., Iwakura Y., et al. CCL2 recruitment of IL-6-producing CD11b+ monocytes to the draining lymph nodes during the initiation of Th17-dependent B cell-mediated autoimmunity. Eur J Immunol 2008, 38:1877-1888.
14. Aharonov A., Tarrab-Hazdai R., Silman I., Fuchs S. Immunochemical studies on acetylcholine receptor from Torpedo californica. Immunochemistry 1977, 14:129-137.
15. Lennon V.A., Lambert E.H., Leiby K.R., Okarma T.B., Talib S. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol 1991, 146:2245-2248.
16. Arruda J.L., Sweitzer S., Rutkowski M.D., DeLeo J.A. Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res 2000, 879:216-225.
17. Hogan D., Morrow J.D., Smith E.M., Opp M.R. Interleukin-6 alters sleep of rats. J Neuroimmunol 2003, 137:59-66.
18. Smith C., Wilson N.W., Louw A., Myburgh K.H. Illuminating the interrelated immune and endocrine adaptations after multiple exposures to short immobilization stress by in vivo blocking of IL-6. Am J Physiol Regul Integr Comp Physiol 2007, 292:R1439-R1447.
19. Aricha R., Feferman T., Souroujon M.C., Fuchs S. Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor. FASEB J 2006, 20:374-376.
20. Maiti P.K., Feferman T., Im S.H., Souroujon M.C., Fuchs S. Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment. J Neuroimmunol 2004, 152:112-120.
21. Aricha R., Feferman T., Fuchs S., Souroujon M.C. Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis. J Immunol 2008, 180:2132-2139.
22. Korn T., Mitsdoerffer M., Croxford A.L., Awasthi A., Dardalhon V.A., Galileos G., et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A 2008, 105:18460-18465.
23. Masuda M., Matsumoto M., Tanaka S., Nakajima K., Yamada N., Ido N., et al. Clinical implication of peripheral CD4(+)CD25(+) regulatory T cells and Th17 cells in myasthenia gravis patients. J Neuroimmunol 2010, 225:123-131.
24. Mu L., Sun B., Kong Q., Wang J., Wang G., Zhang S., et al. Disequilibrium of T helper type 1, 2 and 17 cells and regulatory T cells during the development of experimental autoimmune myasthenia gravis. Immunology 2009, 128:e826-e836.
25. Li H., Shi F.D., Bai X., Huang Y., Diab A., He B., et al. Cytokine and chemokine mRNA expressing cells in muscle tissues of experimental autoimmune myasthenia gravis. J Neurol Sci 1998, 161:40-46.
26. Acosta-Rodriguez E.V., Napolitani G., Lanzavecchia A., Sallusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007, 8:942-949.
27. Volpe E., Servant N., Zollinger R., Bogiatzi S.I., Hupe P., Barillot E., et al. A critical function for transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol 2008, 9:650-657.
28. Yang Y., Xu J., Niu Y., Bromberg J.S., Ding Y. T-bet and eomesodermin play critical roles in directing T cell differentiation to Th1 versus Th17. J Immunol 2008, 181:8700-8710.
29. Duan R.S., Wang H.B., Yang J.S., Scallon B., Link H., Xiao B.G. Anti-TNF-alpha antibodies suppress the development of experimental autoimmune myasthenia gravis. J Autoimmun 2002, 19:169-174.
30. Moiola L., Galbiati F., Martino G., Amadio S., Brambilla E., Comi G., et al. IL-12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody-mediated disease. Eur J Immunol 1998, 28:2487-2497.
31. Wang W., Milani M., Ostlie N., Okita D., Agarwal R.K., Caspi R., et al. C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-gamma are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. J Immunol 2007, 178:7072-7080.
32. Fujimoto M., Serada S., Mihara M., Uchiyama Y., Yoshida H., Koike N., et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008, 58:3710-3719.
33. Hohki S., Ohguro N., Haruta H., Nakai K., Terabe F., Serada S., et al. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses. Exp Eye Res 2010, 91:162-170.
34. Mihara M., Ohsugi Y., Kishimoto T. Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibody. Biofactors 2009, 35:47-51.
35. Serada S., Fujimoto M., Mihara M., Koike N., Ohsugi Y., Nomura S., et al. IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008, 105:9041-9046.
36. Zhou L., Lopes J.E., Chong M.M., Ivanov, Min R., Victora G.D., et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing ROR gammat function. Nature 2008, 453:236-240.
37. Kopf M., Herren S., Wiles M.V., Pepys M.B., Kosco-Vilbois M.H. Interleukin 6 influences germinal center development and antibody production via a contribution of C3 complement component. J Exp Med 1998, 188:1895-1906.
38. Hsu H.C., Yang P., Wang J., Wu Q., Myers R., Chen J., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008, 9:166-175.